3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Neoplasms
5
Pain
2
Constipation
2
Cancer Pain
2
Bronchiolitis Obliterans Syndrome
2
Osteoarthritis
1
Lymphoma, Follicular
1
Intestinal Obstruction
1
Back Pain
1
Interventions
Morphine
15
Oxycodone
13
Fentanyl
9
nabiximols
5
Methadone
5
Lidocaine
5
Acetaminophen
5
resiniferatoxin
4
Ethanol
4
Acupuncture Therapy
4
Transcutaneous Electric Nerve Stimulation
3
Hydromorphone
3
Transcranial Direct Current Stimulation
2
Surveys and Questionnaires
2
Standard of Care
2
Sodium Bicarbonate
2
Radiofrequency Ablation
2
Pharmaceutical Services
2
Naloxone
2
Ketamine
2
Electroacupuncture
2
Dronabinol
2
Control Groups
2
Buprenorphine
2
Analgesics, Opioid
2
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
2
tanezumab
1
rofecoxib
1
naloxegol
1
incobotulinumtoxinA
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Cancer Pain
×
Naloxone
×
Clear all
NCT01313780
2017-12-22
TOP
Mundipharma Korea Ltd
Phase 4
Completed
128 enrolled
8 charts
NCT01719757
2016-08-19
PROBE
Mundipharma Korea Ltd
Phase 4
Completed
359 enrolled
10 charts